Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Antiamyloid Therapy for Alzheimer's Disease — Are We on the Right Road?

Karran, Eric, Hardy, John · 2014 · New England Journal of Medicine

Abstract

The increasing prevalence of Alzheimer's disease represents a global challenge at multiple levels: personal, social, and economic. The amyloid hypothesis1 posits that deposition of amyloid-beta (Aβ) in brain parenchyma is an early critical event in Alzheimer's disease that promotes or accelerates downstream features of the disease such as tangle formation, neuronal loss, and progressive dementia. Most pharmaceutical companies seeking disease-modifying treatments for Alzheimer's disease have investigated Aβ-centric therapeutics.This issue of the Journal contains reports on the phase 3 trials in Alzheimer's disease of two anti-Aβ antibodies: bapineuzumab2 and solanezumab.3 Each agent was tested in two trials. Both sets of . . .

Overview

Integrity signals

Registry

Crossref · 10.1056/nejme1313943

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 7 references

Research works printed but not linked: 2

  1. 10.1056/nejmoa1304839 · DOI · Paper page
  2. 10.1056/nejmoa1312889 · DOI · Paper page

Cited by

See all 129

Metadata

Authors
Karran, E., & Hardy, J.
Affiliations
  • Alzheimer’s Research UK (GB)
  • University College London (GB)
Venue
New England Journal of Medicine
Published
2014-01-23
Volume
370
Issue
4
Pages
377-378
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2030067782
Cited by
126
References
7
Citations by year
2026: 2 · 2025: 7 · 2024: 7 · 2023: 1 · 2022: 6 · 2021: 3 · 2020: 7 · 2019: 7 · 2018: 9 · 2017: 7 · 2016: 19 · 2015: 26 · 2014: 24
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, amyloid-beta, anti-amyloid therapy, amyloid hypothesis, bapineuzumab, solanezumab, anti-amyloid antibodies, disease-modifying therapy
MeSH terms
Alzheimer Disease, Female, Humans, Male, Amyloid beta-Peptides, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antiamyloid Therapy for Alzheimer's Disease — Are We on the Right Road? https://app.cochat.ai/papers/10.1056/nejme1313943
The paper
Karran, E., & Hardy, J. (2014). Antiamyloid Therapy for Alzheimer's Disease — Are We on the Right Road? New England Journal of Medicine. https://doi.org/10.1056/nejme1313943

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.